Aripiprazole Augmentation in Treatment-Resistant Schizophrenia

Introduction to Aripiprazole Augmentation

• The American Psychiatric Association recommends aripiprazole as the preferred augmentation agent for clozapine in treatment-resistant schizophrenia, with medium-dose aripiprazole (9 to <16.5 mg/day) combined with high-dose clozapine (≥330 mg/day) reducing severe relapse risk 1

Guideline Framework

• Current treatment guidelines establish a clear hierarchy for treatment-resistant schizophrenia, where clozapine monotherapy should be initiated after two adequate trials of non-clozapine antipsychotics have failed 4
• If clozapine-tolerant with residual symptoms, augment with a partial D2-agonist (aripiprazole) 1
• If clozapine-intolerant, consider non-clozapine antipsychotic polypharmacy 1

Dosing Algorithm

• For patients on high-dose clozapine (≥330 mg/day), start aripiprazole at 5 mg/day and titrate to 9-16.5 mg/day (medium dose), as this combination provides the strongest evidence for relapse prevention 1
• For patients on medium-dose clozapine (180-330 mg/day), start aripiprazole at 5 mg/day and titrate to 9-16.5 mg/day (medium dose) 1

Monitoring and Documentation

• Clearly record baseline symptomatology before initiating augmentation 1
• Essential follow-up after initiation to assess benefit 3
• If no improvement occurs, revert to monotherapy or explore other combinations 3
• If stable improvement achieved, consider gradual reduction back to monotherapy as many patients tolerate this transition 1